206 related articles for article (PubMed ID: 38152697)
1. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO; Quiroga D; Johnson C; Brufsky A; Chambers M; Bhattacharya S; Patterson M; Sardesai SD; Stover D; Lustberg M; Noonan AM; Cherian M; Bystry DM; Hill KL; Chen M; Phelps MA; Grever M; Stephens JA; Ramaswamy B; Carson WE; Wesolowski R
Ther Adv Med Oncol; 2023; 15():17588359231217976. PubMed ID: 38152697
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.
Do K; Speranza G; Chang LC; Polley EC; Bishop R; Zhu W; Trepel JB; Lee S; Lee MJ; Kinders RJ; Phillips L; Collins J; Lyons J; Jeong W; Antony R; Chen AP; Neckers L; Doroshow JH; Kummar S
Invest New Drugs; 2015 Aug; 33(4):921-30. PubMed ID: 26082332
[TBL] [Abstract][Full Text] [Related]
4. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Malhotra MK; Pahuja S; Kiesel BF; Appleman LJ; Ding F; Lin Y; Tawbi HA; Stoller RG; Lee JJ; Belani CP; Chen AP; Giranda VL; Shepherd SP; Emens LA; Ivy SP; Chu E; Beumer JH; Puhalla S
Breast Cancer Res Treat; 2023 Apr; 198(3):487-498. PubMed ID: 36853577
[TBL] [Abstract][Full Text] [Related]
7. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE; Saleem S; Damodaran S; Somaiah N; Piha-Paul S; Moore JA; Yilmaz B; Ogbonna D; Karp DD; Dumbrava E; Tsimberidou AM; Hong DS; Rodon Ahnert J; Milton DR; Zheng X; Booser DJ; Ibrahim NK; Conley AP; Bhosale P; Rojas Hernandez CM; Tripathy D; Naing A; Meric-Bernstam F
Cancer; 2023 Jul; 129(14):2201-2213. PubMed ID: 37016732
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Sharma P; Abramson VG; O'Dea A; Nye L; Mayer I; Pathak HB; Hoffmann M; Stecklein SR; Elia M; Lewis S; Scott J; De Jong JA; Wang YY; Yoder R; Schwensen K; Finke K; Heldstab J; LaFaver S; Williamson SK; Phadnis MA; Reed GA; Kimler BF; Khan QJ; Godwin AK
Clin Cancer Res; 2021 Jul; 27(14):3896-3904. PubMed ID: 33602685
[TBL] [Abstract][Full Text] [Related]
10. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
Ruiz-Borrego M; Jimenez B; Antolín S; García-Saenz JA; Corral J; Jerez Y; Trigo J; Urruticoechea A; Colom H; Gonzalo N; Muñoz C; Benito S; Caballero R; Bezares S; Carrasco E; Rojo F; Martín M
Invest New Drugs; 2019 Feb; 37(1):98-108. PubMed ID: 29948356
[TBL] [Abstract][Full Text] [Related]
11. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
Lee JS; Yost SE; Blanchard S; Schmolze D; Yin HH; Pillai R; Robinson K; Tang A; Martinez N; Portnow J; Wen W; Yim JH; Brauer HA; Ren Y; Luu T; Mortimer J; Yuan Y
Breast Cancer Res; 2019 Nov; 21(1):119. PubMed ID: 31703728
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
[TBL] [Abstract][Full Text] [Related]
14. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Wesolowski R; Stover DG; Lustberg MB; Shoben A; Zhao M; Mrozek E; Layman RM; Macrae E; Duan W; Zhang J; Hall N; Wright CL; Gillespie S; Berger M; Chalmers JJ; Carey A; Balasubramanian P; Miller BL; Amaya P; Andreopoulou E; Sparano J; Shapiro CL; Villalona-Calero MA; Geyer S; Chen A; Grever MR; Knopp MV; Ramaswamy B
Oncologist; 2020 Aug; 25(8):e1158-e1169. PubMed ID: 32452601
[TBL] [Abstract][Full Text] [Related]
15. Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.
Ray-Coquard I; Braicu I; Berger R; Mahner S; Sehouli J; Pujade-Lauraine E; Cassier PA; Moll UM; Ulmer H; Leunen K; Zeimet AG; Marth C; Vergote I; Concin N
Front Oncol; 2019; 9():832. PubMed ID: 31552170
[No Abstract] [Full Text] [Related]
16. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
Shapiro GI; Kwak E; Dezube BJ; Yule M; Ayrton J; Lyons J; Mahadevan D
Clin Cancer Res; 2015 Jan; 21(1):87-97. PubMed ID: 25336693
[TBL] [Abstract][Full Text] [Related]
17. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
[TBL] [Abstract][Full Text] [Related]
18. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Vicier C; Sfumato P; Isambert N; Dalenc F; Robert M; Levy C; Rezai K; Provansal M; Adélaïde J; Garnier S; Guille A; Carbuccia N; Popovici C; Charafe-Jauffret E; Chaffanet M; Birnbaum D; Pakradouni J; Bertucci F; Boher JM; Sabatier R; Gonçalves A
Eur J Cancer; 2021 Dec; 159():205-214. PubMed ID: 34781168
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).
Awada A; Bondarenko IN; Bonneterre J; Nowara E; Ferrero JM; Bakshi AV; Wilke C; Piccart M;
Ann Oncol; 2014 Apr; 25(4):824-831. PubMed ID: 24667715
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.
Slovin S; Hussain S; Saad F; Garcia J; Picus J; Ferraldeschi R; Crespo M; Flohr P; Riisnaes R; Lin C; Keer H; Oganesian A; Workman P; de Bono J
Clin Cancer Res; 2019 Aug; 25(15):4624-4633. PubMed ID: 31113841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]